web analytics

Tolerizing Agonist/Immunomodulator Loaded Liposomes for Long-Lived Immune Tolerance

Published:
Lead Inventor: Aaron Esser-Kahn
Print or Save to PDF

SUMMARY

  • A failure of central immune tolerance typically driven by autoantigen specific T regulatory (Treg) cells is the primary cause of many autoimmune diseases.

  • This technology generates antigen specific immune tolerance for autoimmune or transplantation therapy via induction of tolerogenic dendritic cells (tolDC, PD-L1+, CD80- CD11c+)) which facilitate the differentiation of antigen specific Tregs.

  • The invention is a liposome loaded with immunosuppressive drugs, toll-like-receptor (TLR) agonists, and any antigen of interest.  This unique co-formulation of activating and inhibitory signals generates a potent toIDC phenotype in vivo.

 

FIGURE

Tolerogenic Liposomes Prevent EAE Disease Progression via Antigen Specific Bystander Tolerance.
(A) Mice were treated on day 4 and 5 (following EAE induction), allowed to rest for 48 hrs then treated again on day 7 and 8. After final treatment, mice were monitored for 37 days. (B) Mice were treated similarly, but sacrificed on day 14 following EAE induction. Serum was taken and analyzed for EAE peptide specific IgG levels via ELISA. UT denotes an “untreated” mouse without MOG exposure.

 

ADVANTAGES

ADVANTAGES

  • Reliable generation of antigen specific Tregs with minimal non-specific immune suppression

  • Long-lived immune tolerance

  • Easy manufacturing and storage

 

APPLICATIONS

  • Autoimmune diseases
  • Transplant medicine

PUBLICATIONS

  • Manuscript under review
  • In vivo experiments performed